Carbios SAS to expand PET recycling portfolio to the UK
French bioplastics recycling specialist Carbios SAS and British recycling and waste management company FCC Environment want to establish a PET biorecycling facility in the UK.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1300 entries already.
Entries by Thomas Gabrielczyk
FDA approves cell therapy for solid tumours
/in News/by Thomas GabrielczykThe US Food & Drug Administration has granted accelerated approval to Adaptimmune’s Tecelra as the world’s first therapy with genetically engineered T cells to fight a solid tumour.
Valneva licences LimmaTech’s Shigella vaccine
/in News/by Thomas GabrielczykFrench-Austrian vaccine maker Valneva SE has secured exclusive worldwide rights to commercialise LimmaTech Biologics AG’s S4V Shigella vaccine that will be tested in two Phase II trials starting in H2/2024.
BI Venture Funds invests in oncolytic bacteria
/in News/by Thomas GabrielczykWith an investment of its venture arm (BI-VF), Boehringer Ingelheim underlines its committment to expand the reach of cancer immune therapies. The Series A financing in Chinese Synthetica Pioneering that engineers oncolytic bacteria to deliver toxic payloads or modulators of the tumour environment to solid tumours follows an investment in T3 Pharmaceuticals.
GSK and Flagship Pioneering ink US$7.2bn biobucks discovery deal
/in News/by Thomas GabrielczykAs one of the last Big Pharma companies, GlaxoSmithKline plc has inked a drug discovery licence option deal for up to 10 programmes with US-based biotech platform company supplier Flagship Pioneering Inc.
Gourmey files first EU application for cell-based meat
/in News/by Thomas GabrielczykNot the German InFamily Foods subsidiary The Cultivated B, but Gourmey SAS, founded in Paris in 2019 by Antoine Davydoff, Nicolas Morin-Forest and Victor Sayous, has submitted the first EU authorisation application for a cell-based meat product, a duck liver pâté (Foie gras), to the European Food Safety Authority (EFSA).
Confo Therapeutics closes €60m Series B financing
/in News/by Thomas GabrielczykBelgian GPCR specialist Confo Therapeutics NV has raised €60m in an Series B financing round led by Ackermans & van Haaren to advance clinical development of two clinical programmes and preclinical candidates to treat rare endocrine diseases and obesity.
AC Immune bags FDA fast track designation
/in News/by Thomas GabrielczykSwiss AC Immune and its partner Janssen Pharmaceuticals Inc have been granted FDA Fast Track Designation for their active anti-pTau vaccine ACI-35.030/JNJ-2056 to treat Alzheimer’s disease.
New targets for incurable blood cancer
/in News/by Thomas GabrielczykA research consortium led by Charité in Berlin has found a protein pattern in 100 patients with the common blood cancer multiple myeloma and 38 healthy controls that independently identifies a poor prognosis and provides new targets for treating the incurable disease.
SynaptixBio Ltd and Evotec SE expand collaboration
/in News/by Thomas GabrielczykEvotec SE is widening its 2022 R&D collaboration SynaptixBio Ltdi to optimise and identify new antisense oligonucleotides to treat children with H-ABC leukodystrophy, a rare genetic myelin synthesis defect that shows similar symptoms such as multiple sclerosis.